Reneo Pharmaceuticals Analyst Ratings
Mitchell Kapoor's Hold Rating on Reneo Pharmaceuticals Amid OnKure Merger and Oncology Pipeline Potential
Maintaining Hold on Reneo Pharmaceuticals Amidst Strategic Uncertainties and Pipeline Setbacks
Sell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Target
Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC)
Reneo Pharmaceuticals Analyst Ratings
Hold Rating and Lowered Price Target for Reneo Pharmaceuticals Following STRIDE Study Setback and Operational Challenges
Baird Downgrades Reneo Pharmaceuticals to Neutral From Outperform, Cuts Price Target to $3 From $28
Reneo Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Reneo Pharmaceuticals, Maintains $30 Price Target
Reneo Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Reneo Pharmaceuticals (RPHM), Astria Therapeutics (ATXS) and Scholar Rock Holding (SRRK)
HC Wainwright & Co. Reiterates Buy on Reneo Pharmaceuticals, Maintains $30 Price Target
Reneo Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Reneo Pharmaceuticals (RPHM), Pulmonx (LUNG) and Orchestra BioMed Holdings (OBIO)
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Reneo Pharmaceuticals (RPHM)
HC Wainwright & Co. Reiterates Buy on Reneo Pharmaceuticals, Maintains $30 Price Target
Reneo Pharmaceuticals Analyst Ratings
H.C. Wainwright Keeps Their Buy Rating on Reneo Pharmaceuticals (RPHM)
HC Wainwright & Co. Initiates Coverage On Reneo Pharmaceuticals With Buy Rating, Announces Price Target of $30